Information Provided By:
Fly News Breaks for January 3, 2019
FLDM
Jan 3, 2019 | 08:01 EDT
As previously reported, Janney Montgomery Scott analyst Paul Knight upgraded Fluidigm to Buy from Neutral, stating that new management has repositioned the business to benefit from the paradigm shift in immuno-oncology while also refocusing its Genomics group. Noting that the company cites growing interest in CAR-T cell therapies and other immuno-oncology therapies as a key driver in its Mass Cytometry growth, Knight said he estimate Mass Cytometry sales will grow at approximately 20% annually from FY18 through FY22. He raised his fair value estimate on Fluidigm shares to $12 from $9.
News For FLDM From the Last 2 Days
There are no results for your query FLDM